Cargando…
Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors
BACKGROUND: Few studies have focused on the impact of single-organ pulmonary metastases on progression-free survival and overall survival in patients with metastatic colorectal cancer. Recognizing differences in prognosis and chemotherapeutic efficacy based on metastasized organs may help in optimiz...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327308/ https://www.ncbi.nlm.nih.gov/pubmed/37415118 http://dx.doi.org/10.1186/s12885-023-11067-y |
_version_ | 1785069596261220352 |
---|---|
author | Fukuda, Koshiro Osumi, Hiroki Yoshino, Koichiro Nakayama, Izuma Fukuoka, Shota Ogura, Mariko Wakatsuki, Takeru Ooki, Akira Takahari, Daisuke Chin, Keisho Yamaguchi, Kensei Shinozaki, Eiji |
author_facet | Fukuda, Koshiro Osumi, Hiroki Yoshino, Koichiro Nakayama, Izuma Fukuoka, Shota Ogura, Mariko Wakatsuki, Takeru Ooki, Akira Takahari, Daisuke Chin, Keisho Yamaguchi, Kensei Shinozaki, Eiji |
author_sort | Fukuda, Koshiro |
collection | PubMed |
description | BACKGROUND: Few studies have focused on the impact of single-organ pulmonary metastases on progression-free survival and overall survival in patients with metastatic colorectal cancer. Recognizing differences in prognosis and chemotherapeutic efficacy based on metastasized organs may help in optimizing treatment strategies. The exploratory study was conducted to evaluate the comparative clinical outcomes and prognoses of patients with metastatic colorectal cancer presenting with single-organ pulmonary metastases and treated with folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors as second-line chemotherapy. METHODS: This retrospective study included 289 patients with metastatic colorectal cancer treated with second-line folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors. The response rate, disease control rate, progression-free survival, and overall survival were assessed in the participants. RESULTS: Among the 289 patients enrolled, 26 (9.0%) had single-organ pulmonary metastasis with left-sided primary locations, lower levels of tumor markers at the initiation point of chemotherapy, a significantly higher disease control rate (96.2% vs. 76.7%, P = .02), and a longer progression-free survival (median 29.6 months vs. 6.1 months, P < .001) and overall survival (median 41.1 months vs. 18.7 months, P < .001) than patients with other forms of metastatic colorectal cancer. Multivariate analysis showed that single-organ pulmonary metastasis was an independent predictor of longer progression-free survival (hazard ratio 0.35, P = .00075) and overall survival (hazard ratio 0.2, P = .006). CONCLUSION: Single-organ pulmonary metastasis was a strong predictor of progression-free survival and overall survival in patients with metastatic colorectal cancer treated with folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors as second-line chemotherapy; this provides preliminary evidence for medical guidelines and clinical decision-making on novel therapeutic strategies for these patients. |
format | Online Article Text |
id | pubmed-10327308 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103273082023-07-08 Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors Fukuda, Koshiro Osumi, Hiroki Yoshino, Koichiro Nakayama, Izuma Fukuoka, Shota Ogura, Mariko Wakatsuki, Takeru Ooki, Akira Takahari, Daisuke Chin, Keisho Yamaguchi, Kensei Shinozaki, Eiji BMC Cancer Research BACKGROUND: Few studies have focused on the impact of single-organ pulmonary metastases on progression-free survival and overall survival in patients with metastatic colorectal cancer. Recognizing differences in prognosis and chemotherapeutic efficacy based on metastasized organs may help in optimizing treatment strategies. The exploratory study was conducted to evaluate the comparative clinical outcomes and prognoses of patients with metastatic colorectal cancer presenting with single-organ pulmonary metastases and treated with folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors as second-line chemotherapy. METHODS: This retrospective study included 289 patients with metastatic colorectal cancer treated with second-line folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors. The response rate, disease control rate, progression-free survival, and overall survival were assessed in the participants. RESULTS: Among the 289 patients enrolled, 26 (9.0%) had single-organ pulmonary metastasis with left-sided primary locations, lower levels of tumor markers at the initiation point of chemotherapy, a significantly higher disease control rate (96.2% vs. 76.7%, P = .02), and a longer progression-free survival (median 29.6 months vs. 6.1 months, P < .001) and overall survival (median 41.1 months vs. 18.7 months, P < .001) than patients with other forms of metastatic colorectal cancer. Multivariate analysis showed that single-organ pulmonary metastasis was an independent predictor of longer progression-free survival (hazard ratio 0.35, P = .00075) and overall survival (hazard ratio 0.2, P = .006). CONCLUSION: Single-organ pulmonary metastasis was a strong predictor of progression-free survival and overall survival in patients with metastatic colorectal cancer treated with folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors as second-line chemotherapy; this provides preliminary evidence for medical guidelines and clinical decision-making on novel therapeutic strategies for these patients. BioMed Central 2023-07-06 /pmc/articles/PMC10327308/ /pubmed/37415118 http://dx.doi.org/10.1186/s12885-023-11067-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Fukuda, Koshiro Osumi, Hiroki Yoshino, Koichiro Nakayama, Izuma Fukuoka, Shota Ogura, Mariko Wakatsuki, Takeru Ooki, Akira Takahari, Daisuke Chin, Keisho Yamaguchi, Kensei Shinozaki, Eiji Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors |
title | Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors |
title_full | Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors |
title_fullStr | Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors |
title_full_unstemmed | Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors |
title_short | Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors |
title_sort | single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with folfiri and vascular endothelial growth factor inhibitors |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327308/ https://www.ncbi.nlm.nih.gov/pubmed/37415118 http://dx.doi.org/10.1186/s12885-023-11067-y |
work_keys_str_mv | AT fukudakoshiro singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors AT osumihiroki singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors AT yoshinokoichiro singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors AT nakayamaizuma singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors AT fukuokashota singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors AT oguramariko singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors AT wakatsukitakeru singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors AT ookiakira singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors AT takaharidaisuke singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors AT chinkeisho singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors AT yamaguchikensei singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors AT shinozakieiji singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors |